Citation Impact
Citing Papers
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition
2022 StandoutNobel
TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies
2019
Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
2017 Science
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis
2012
Targeted glycan degradation potentiates the anticancer immune response in vivo
2020 StandoutNobel
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
2013
Engineered receptors for soluble cellular communication and disease sensing
2024 StandoutNatureNobel
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Engineering precision nanoparticles for drug delivery
2020 Standout
Dendritic cells in cancer immunology and immunotherapy
2019 Standout
T cell immunotherapy enhanced by designer biomaterials
2019
The polarization of immune cells in the tumour environment by TGFβ
2010
Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?
2021
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
2019 Standout
Hepatocellular carcinoma
2016 Standout
Cancer to bone: a fatal attraction
2011 Standout
Combination cancer immunotherapy and new immunomodulatory targets
2015
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma
2012
Transforming Growth Factor-β Signaling in Immunity and Cancer
2019 Standout
TGFβ signalling in context
2012 Standout
Polysialic acids: potential in drug delivery
1993
TGF-β: the master regulator of fibrosis
2016 Standout
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
The Molecular Signatures Database Hallmark Gene Set Collection
2015 Standout
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Cancer stem cells revisited
2017 Standout
In situ immune response and mechanisms of cell damage in central nervous system of fatal cases microcephaly by Zika virus
2018 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor β Superfamily Type 1 Receptors
2018
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer
2017 StandoutNobel
Targeting the transforming growth factor-β signalling pathway in metastatic cancer
2010
Microfluidic organs-on-chips
2014 Standout
Immunoregulation by members of the TGFβ superfamily
2016
Next generation of immune checkpoint therapy in cancer: new developments and challenges
2018
Targeting the TGFβ signalling pathway in disease
2012
Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions
2016
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Emerging Biological Principles of Metastasis
2017 Standout
Programmed Cell Senescence during Mammalian Embryonic Development
2013 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
EMT: 2016
2016 Standout
TGFβ in Cancer
2008 Standout
T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine
2011 StandoutNobel
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
2016 Standout
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
2018 Nature
Macrophages as regulators of tumour immunity and immunotherapy
2019 Standout
Eicosanoids and cancer
2010 Standout
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer
2017 Standout
PGE2 and LTB4 tissue levels in benign and cancerous prostates
2008
Future directions of bone-targeted therapy for metastatic breast cancer
2010
Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models
2017
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
2015
Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment
2018
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
The dawning era of polymer therapeutics
2003 Standout
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
2018
Signaling Receptors for TGF-β Family Members
2016
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
2018 Standout
Activin receptor‐like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes
2014
Activin receptor‐like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes
2013
Antibodies to poly[(2----8)-alpha-N-acetylneuraminic acid] and poly[(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1.
1991
Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma
2019
Polysialic Acid, a Glycan with Highly Restricted Expression, Is Found on Human and Murine Leukocytes and Modulates Immune Responses
2008 StandoutNobel
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
2022 StandoutNobel
Peptidic degron for IMiD-induced degradation of heterologous proteins
2019 StandoutNobel
Natural Innate and Adaptive Immunity to Cancer
2011 Standout
Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors
2017
Transforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy
2007
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer
2020
Multidimensional imaging provides evidence for down-regulation of T cell effector function by MDSC in human cancer tissue
2019
Targeting the TGFβ pathway for cancer therapy
2014
Flow-based pipeline for systematic modulation and analysis of 3D tumor microenvironmentsâ \nâ Electronic supplementary information (ESI) available. See DOI: 10.1039/c3lc41300dClick here for additional data file.\n\n
2013
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner
2015
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Transforming Growth Factor-β as a Therapeutic Target in Hepatocellular Carcinoma
2014
Works of Ann Cleverly being referenced
First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma
2014
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
2018
Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study
2014
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer
2019
TGF-β signalling-related markers in cancer patients with bone metastasis
2008
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors
2011
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
2014
Immunogenicity in adult males of a Neisseria meningitidis group B vaccine composed of polysaccharide complexed with outer membrane proteins
1991
A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer
2014
Development and validation of a phosphorylated SMADex vivostimulation assay
2007
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
2016
First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma.
2011
Integrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor, LY2157299 monohydrate (LY).
2013
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
2019
A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC).
2014
Defining a therapeutic window for the novel TGF ‐β inhibitor LY 2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model
2013
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
2015
Phase I and Pharmacokinetic Study of LY293111, an Orally Bioavailable LTB4 Receptor Antagonist, in Patients With Advanced Solid Tumors
2005
The oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study.
2012
First human dose escalation study in patients with metastatic malignancies to determine safety and pharmacokinetics of LY2157299, a small molecule inhibitor of the transforming growth factor-beta receptor I kinase
2008
Phase I study of LY573636-sodium, an acylsulfonamide anti-cancer compound with a novel mechanism of action, administered as 2-hour IV infusion in patients with advanced solid tumors
2007
Randomized dose comparison phase II study of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) in patients with advanced hepatocellular carcinoma (HCC).
2013